AstraZeneca to acquire Fusion Pharmaceuticals for next-generation cancer drug development
AstraZeneca has agreed to acquire Fusion Pharmaceuticals, a clinical-stage company specializing in radioconjugates. The deal aims to accelerate the development of novel, targeted cancer treatments.
Pharmaceutical giant AstraZeneca has entered into an agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on developing next-generation radioconjugates (RCs). This acquisition represents a significant step for AstraZeneca in its goal to transform cancer care and improve patient outcomes by replacing traditional treatments with more targeted therapies.
Radioconjugates have emerged as a promising modality in cancer treatment. These medicines work by delivering a radioactive isotope directly to cancer cells using precisely targeting molecules such as antibodies or peptides. This approach has the potential to minimize damage to healthy cells and reach tumors inaccessible to conventional radiotherapy.
The acquisition grants AstraZeneca access to Fusion's pipeline of radioconjugates, including its most advanced program, FPI-2265. This treatment is intended for patients with prostate cancer and targets the PSMA protein, which is highly expressed in metastatic castration-resistant prostate cancer. FPI-2265 is currently in Phase II clinical trials.
The deal brings new expertise and capabilities to AstraZeneca in the research, development, and manufacturing of actinium-based radioconjugates. It also strengthens the company's presence in Canada.
The transaction is expected to close in the second quarter of 2024. The acquisition price includes an upfront cash payment and a contingent value right tied to the achievement of a specified regulatory milestone, potentially bringing the total deal value to approximately $2.4 billion.